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Expression of somatostatin in the adult and developing mouse
kidney.
Background. Somatostatin (somatotropin release inhibiting
factor) (SRIF) has potent antiproliferative and antisecretory
actions. In the adult kidney, somatostatin alters renal blood
flow, ion transport, and water permeability. While some evi-
dence suggests that SRIF may be produced by adult kidney
tubular cells, the specific tubules generating SRIF are unknown.
Somatostatin has also been detected in a variety of embryonic
tissues, although it has not been described in the developing
kidney. Our objective was to determine the expression pattern
of SRIF in both the adult and embryonic mouse kidney.
Methods. We performed reverse transcriptase-polymerase
chain reaction (RT-PCR) and immunofluorescence for SRIF
in developing and adult mouse kidney tissues. We localized
SRIF by dual or serial labeling immunofluorescence with spe-
cific markers.
Results. Somatostatin mRNA was present in kidneys
throughout embryogenesis and into adulthood. Starting at
embryonic day (E) 12.5, SRIF was strongly expressed at the
interface of the metanephric mesenchymal cells and the basolat-
eral surfaces of ureteric bud trunks. Starting at E16.5, the stain-
ing at the interface was confined to the peripheral ureteric bud
trunks and the clefts of newly dividing ureteric bud ampullae.
In older embryos, SRIF also appeared in medullary tubules that
appeared to be maturing thin descending limbs of Henle. In the
adult kidney, SRIF proteins localized exclusively to medullary
thin descending limbs of the Henle loop.
Conclusion. In embryonic kidneys, SRIF is expressed first
at the interface of the metanephric mesenchyme and basolat-
eral ureteric bud and later in maturing thin descending limbs
of Henle. Expression in the thin descending limb persists in the
adult kidney.
Somatostatin, a 14 or a 28 amino acid peptide, is gen-
erated by sequential cleavage of N-terminal amino acids
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from a pre-pro and then a pro-peptide [1]. Somatostatin is
highly conserved with 97% amino acid identity between
human and rodent pre-pro peptides and 100% identity
between human and rodent 14 and 28 amino acid pep-
tides [1]. Somatotropin release inhibiting factor (SRIF)
signaling is mediated via five different G-protein–coupled
receptors, somatostatin receptors (SSTRs) 1 to 5 [1]. So-
matostatin acts in the brain as a neurotransmitter and in
a variety of primary and neoplastic tissues as an inhibitor
of cell proliferation and/or an inhibitor of cell secretion
[1]. In the adult metanephric kidney, somatostatin alters
glomerular filtration and renal blood flow [2–4], inhibits
tubular phosphate transport [2, 3, 5], and alters urine vol-
ume and free-water clearance [5–7].
In addition to having actions in the adult kidney, so-
matostatin appears to be produced in the kidney; how-
ever, the specific renal cells that generate somatostatin
have either not been identified and/or may vary by
species. Primary human glomerular mesangial cell cul-
tures were reported to express somatostatin mRNA and
to secrete the peptide into the media [8]. In rats, however,
SRIF immunostaining was described in isolated glomeru-
lar cells that were clearly not mesangial cells (and in only
one out of every five to ten glomeruli per 4 lm section) [9].
Heterogeneous mixtures of primary human renal tubu-
lar cells have also been reported to express somatostatin
mRNA and to secrete the peptide into the media, but the
specific tubular cells generating somatostatin were not
identified [10].
Unlike the adult kidney, somatostatin expression
has never been described in the developing kidney.
Metanephric kidney development in the mouse begins at
gestational day 11.5 (of a 19-day gestational period) when
an evagination of the caudal nephric duct, the ureteric
bud, contacts adjacent paired densities of mesodermal
tissue, called the metanephric mesenchyme [11]. The mes-
enchyme stimulates the ureteric bud to repeatedly form
ampullae that separate into two tips, which eventually
elongate into new trunks [11]. In turn, each ureteric
bud tip induces local areas of mesenchyme to convert
into nephron epithelia [11]. As development proceeds,
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maturing ureteric buds fuse with the nephrons and form
the collecting ducts [11].
The purpose of our study was to describe the expression
of somatostatin in the adult and developing mouse kid-
ney. By reverse transcription-polymerase chain reaction
(RT-PCR) followed by Southern blotting, we detected
mRNA for somatostatin in mouse kidneys starting in
young embryos and persisting into adulthood. In early
embryonic kidneys, we detected strong somatostatin la-
beling at the interface of the metanephric mesenchyme
and the basolateral surfaces of central ureteric bud
trunks. In more mature embryos, the interface staining
was confined to outer cortical regions around peripheral
ureteric bud trunks and in clefts of ureteric bud ampul-
lae as they began to divide. In older embryos, somato-
statin also appeared in maturing medullary tubules that
expressed markers consistent with thin descending limbs
of Henle. In the adult kidney, somatostatin immunostain-
ing was exclusively in medullary thin descending limbs of
the Henle loop.
METHODS
RT-PCR and Southern blotting
The procedures used were outlined in detail previ-
ously [12]. Briefly, brains from 2- to 4-month-old CD-1
mice and kidneys from embryonic day (E) 12.5, E14.5,
E16.5, E18.5, postnatal day (P) 14, and 2- to 4-month-
old CD-1 mice were homogenized in Trizol (Invitro-
gen, Carlsbad, CA, USA). After addition of chloro-
form, the RNA was precipitated and resuspended in
diethylpyrocarbonate-treated (DEPC) water. Any con-
taminating genomic DNA was digested with RNAse free
RQ1 DNAse (Promega, Madison, WI, USA). The RNA
was again precipitated and resuspended in DEPC water.
RT-PCR was performed at least three times for each
sample. Kidney and brain total RNA samples were re-
verse transcribed with Moloney-murine leukemia virus
(MMLV) Reverse Transcriptase (Promega) or had ster-
ile water added as a negative control. The RT+, RT−
and control genomic samples were then subjected to PCR
amplification for both somatostatin and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH). The oligonu-
cleotide primer sequences and the expected band sizes
for each amplification are listed in Table 1. RT+, RT−,
and genomic samples were amplified with Taq DNA poly-
merase (Invitrogen) for 35 total cycles for SRIF and for
25 cycles for GAPDH. The PCR products were elec-
trophoresed on agarose gels with ethidium bromide.
To verify that the ethidium RT+ PCR bands repre-
sented amplified somatostatin cDNA, we performed
Southern blotting. After depurination, denaturation,
and neutralization, the DNA was then transferred by
capillary action and crosslinked to Magna Nylon mem-
branes (Micron Separations, Inc., Westboro, MA, USA).
After prehybridization, the membranes were hybridized
Table 1. Polymerase chain reaction (PCR) primer constructs
Gene Primer pairs Size bp
SRIF 5′-GTCCTGGCTTT 383 (cDNA)
GGGCGGTGTCA-3′
3′-TAGAGAAGGAATT 1048 (genomic)
GAGGACCGGGG-5′
GAPDH 5′-CTGACGTGCC 346
GCCTGGAGAAA-3′
3′-GATAGGGTTGAGCC
GGGGGTTGT-5′
Abbreviations are: SRIF, somatotropin release inhibiting factor; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
overnight with an [a-32P]-adenosine triphosphate
(ATP) (Amersham, Piscataway, NJ, USA) end-labeled
dephosphorylated oligonucleotide (5′-GACCTCTGA
TCCCTCTCCCCCAAACCCCATATCTCTTCCTTA-
3′), whose sequence is contained within the PCR
fragment. Probes against the ladder DNA were made
by end labeling 25 ng of ladder itself. After washes, the
membranes were exposed to x-ray film. Images were
scanned and converted to Adobe Photoshop files.
Animals and tissue sectioning for immunostaining
For the experiments in adult mice, at least three 2- to
4-month-old CD-1 female mice were used for each histo-
logic experiment. Prior to the experiments, the mice were
maintained on distilled water and standard mouse chow
(Teklad Laboratories, Inc., Indianapolis, IN, USA). For
each experiment, the mice were euthanized by CO2 in-
halation and then the brains and kidneys were removed.
Each organ was divided once with a blade in the mid-
line transverse plane and fixed in Histochoice (Amresco,
Solon, OH, USA) for 4 to 6 hours. For the experiments
in developing kidneys, pregnant CD-1 mice were eu-
thanized as above and embryos at ages E12.5, E14.5,
E16.5, and E18.5 were removed and placed directly in
Histochoice fixative overnight. In addition to CD-1 mice,
Hoxb7GFP transgenic mice that express green fluores-
cent protein (GFP) in ureteric bud tissues [13] (gift from
Frank Costantini, Columbia University) were used for
many of the embryonic experiments. P14 mice were also
euthanized with CO2 and their kidneys removed, divided,
and fixed in the same manner as the adult kidneys.
In preparation for cryostat sectioning, all fixed tissues
were transferred to 25% sucrose overnight at 4◦C. Tissues
were then frozen in 22-oxacalcitriol (OCT) embedding
media (Sakura Finetek, Inc.) in crushed dry ice. The kid-
neys, brains, and embryos were then cryostat sectioned
into 7 to 10 lm slices which were placed on charged glass
microscope slides (Surgipath, Richmond, IL, USA).
Antibodies used for immunofluorescence
SRIF immunostaining in all tissues was performed with
a rabbit polyclonal antibody against the bioactive 14
amino acid peptide at a 1:500 dilution (Bachem, San Car-
los, CA, USA). This antibody has been used previously
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for somatostatin immunostaining in rat neurons [14]. A
second rabbit polyclonal antibody against the 14 amino
acid peptide was used for to confirm the immunostaining
pattern in adult mouse kidneys and brains at a 1:20 di-
lution (Abcam, Cambridge, MA, USA). To further test
the specificity of the SRIF antisera, the 14 amino acid so-
matostatin peptide (Bachem), the 14 amino acid cortis-
tatin peptide (American Peptide Company, Sunnyvale,
CA, USA), and urotensin II (American Peptide Com-
pany) were used for blocking experiments at 10 lg/mL.
For localization studies in developing kidneys, rabbit
polyclonal antibodies against aquaporin 1 (AQP-1) (Al-
pha Diagnostic, San Antonio, TX, USA) were used at
concentrations of 20 lg/mL to label proximal tubules in
the cortex and thin descending limbs of the loop of Henle
in the medulla [15]. Polyclonal antibodies against Golgi
(Affinity BioReagents, Golden, CO, USA) were used at
1:1000. In addition, a mouse monoclonal antibody against
pan cytokeratins (Sigma Chemical Co., St. Louis, MO,
USA) was used at a 1:8 dilution to identify ureteric bud
epithelia [16]. In the Hoxb7GFP transgenic mice, a rabbit
polyclonal antibody against GFP (Molecular Probes, Eu-
gene, OR, USA) was used at a 1:500 dilution to identify
ureteric bud epithelia.
For localizing studies in the adult kidneys, rabbit poly-
clonal antibodies against AQP-1, aquaporin-2 (AQP-2)
(Calbiochem, San Diego, CA, USA), and Tamm-Horsfall
protein (THP) (Biomed Technologies, Lake Hopatcong,
NJ, USA) were used at concentrations of 20 lg/mL, 1:100,
and 1:500, respectively. AQP-2 is a specific marker for the
principal cells of the cortical collecting tubules and corti-
cal and medullary collecting ducts [15]. THP is a specific
marker for the cortical and medullary thick ascending
limbs of the loop of Henle [17].
Secondary antibodies included goat antirabbit cyanine
(Cy)2 conjugates, antirabbit Cy3 conjugates, antirabbit
Cy3 FAB fragments, and antimouse Cy2 conjugates used
at 1:20, 1:500, 1:500, and 1:20, respectively (Jackson Im-
munochemicals, West Grove, PA, USA).
Immunofluorescence
As described previously [12], the tissues were incu-
bated overnight at 4◦C with anti-SRIF or anti-Golgi an-
tisera alone, with SRIF antisera and blocking peptide
(preincubated at room temperature for 2 hours), or with
SRIF antisera and pan cytokeratin antibodies. The tissues
were then incubated with antirabbit Cy3-conjugated an-
tibodies (for the Golgi and most of the SRIF single la-
beling) or with the antirabbit antibodies and antimouse
Cy2 conjugates (for the pan cytokeratin antisera). For
the SRIF and Golgi labeling in serial sections, Cy2 conju-
gates were used to detect SRIF. For the adult kidney dual-
labeling studies, the localizing antirabbit antibodies (i.e.,
AQP-1, AQP-2, and THP antibodies) were applied first,
followed by secondary monovalent Cy3-conjugated FAB
fragments that “converted” each localizing antibody to a
different species [18]. The SRIF antibody was then used
as the second primary antibody, followed by antirabbit
Cy2-conjugated secondary antibodies. For the remaining
dual-labeling studies, SRIF antisera were used as the first
primary antibody (labeled with FAB Cy3 fragments) and
the localizing antibodies (AQP-1 and GFP antibodies)
were used as the second primary antibody (labeled with
Cy2). To control for the possibility of the second antirab-
bit secondary antibody cross-reacting with the first pri-
mary antibody, tissues incubated with the first primary
antibody and antirabbit Cy3-conjugated FAB fragments
were compared with adjacent tissues incubated with the
first primary, the Cy3 FAB secondary and the second Cy2-
conjugated secondary antibody.
Imaging
Images were captured with a MagnaFire digital camera
(Optronics, Goleta, CA, USA) mounted on a DM LB
microscope (Leica, Bannockburn, IL, USA). Files were
then converted to Adobe Photoshop format. Fluorescent
images from dual-labeled slides were superimposed to
generate merged images.
RESULTS
To determine if somatostatin mRNA transcripts were
expressed in the mouse kidney, we performed RT-PCR
followed by Southern blotting. We detected PCR bands
of the appropriate size for somatostatin cDNA in adult
kidney and brain samples that were reverse transcribed
(RT+) and not in control samples without reverse tran-
scriptase (RT−) (Fig. 1A, middle panel). Likewise, we ob-
served bands consistent with somatostatin cDNA in RT+
embryonic (E12.5, E14.5, E16.5, and E18.5) and postna-
tal (P14) mouse kidney samples and not in RT− tissues
(Fig. 1B, top panel). As expected, PCR on genomic DNA
(G) resulted in bands of approximately 1000 bp (Fig. 1A,
middle panel and B, top panel), proving that the smaller
bands in the RT+ samples were not from contaminat-
ing genomic DNA. PCR for GAPDH in the linear range
also revealed bands of the expected size and of relatively
equal intensity in all RT+ samples (not shown). We trans-
ferred all of the PCR products to nylon membranes and
performed Southern blotting with oligonucleotide probes
against portions of somatostatin cDNA expected to be
amplified by the PCR primers. We detected bands only
in the RT+ adult kidney and brain samples (Fig. 1A, right
panel), the RT+ developing kidney samples (Fig. 1B, bot-
tom panel), and genomic samples (Fig. 1). Furthermore,
the Southern bands clearly aligned with the PCR ethid-
ium bands (Fig. 1). Thus, we concluded that mRNA for
somatostatin is expressed in both the adult and develop-
ing mouse kidney.
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Fig. 1. Reverse transcription-polymerase chain reaction (RT-PCR)
and Southern blotting for somatostatin. (A) Compared with a 100 bp
ladder (right panel), PCR ethidium bands of the appropriate size for so-
matotropin release inhibiting factor (SRIF) cDNA are present in kidney
and brain RNA samples with RT added (+) but not in kidney and brain
samples when no RT was added (−) (middle panel). PCR on genomic
DNA (G) reveals a band of approximately 1000 bp as expected (middle
panel). Autoradiographs of Southern blots with specific probes against
SRIF confirm that the ethidium bands in the RT+ and genomic sam-
ples represent amplified cDNA and genomic DNA, respectively (right
panel). (B) PCR bands of the appropriate size for SRIF cDNA are also
present in embryonic (E) E12.5, 14.5, 16.5, 18.5, and postnatal (P) P14
mouse kidney RNA when RT was added but not without RT (−) (top
panel). Southern blots against SRIF again confirm that the PCR bands
represent cDNA and genomic DNA, respectively (lower panel).
We then performed immunofluorescence with somato-
statin antiserum to determine SRIF protein expression in
renal tissues. In young embryonic kidneys, we observed
labeling at the interface of the metanephric mesenchyme
and basolateral surfaces of branching epithelium consis-
tent with ureteric bud tissue (Fig. 2A, arrows). In the
medulla of older embryonic kidneys, we also observed
SRIF staining, suggestive of tubules (Fig. 2C, arrow). In
adult mouse kidneys, we observed widespread somato-
statin staining in medullary epithelial tubules (Fig. 2E,
arrow) and not in the cortex (not shown). To test the
specificity of the antisera, we performed immunofluores-
cence in adult mouse brain tissues and observed staining
of neurons in the fourth layer of the cerebral cortex (Cor)
and the hippocampus (Hc) (Fig. 2K, arrows) as expected
[1]. We also preincubated the antisera with somatostatin-
14 (the immunizing peptide) and completely blocked the
staining in all kidney and brain sections (Fig. 2B, D, F, and
L, arrowheads). In adult kidney sections, we also prein-
cubated the SRIF antisera with cortistatin and urotensin
II (somatostatin-related peptides [19]), but found no de-
crease in signal compared with anti-SRIF antisera alone
(Fig. 2G to J). Thus, we concluded that somatostatin pro-
tein is expressed in both developing and adult mouse
kidneys.
To further characterize the expression of somatostatin
in young embryos, we first utilized Hoxb7GFP trans-
genic mice that express GFP in the ureteric bud. Since
the fixative we used on the tissues quenched most of
the GFP fluorescence, we performed dual-labeling im-
munofluorescence with somatostatin antisera (red) and
anti-GFP antibodies (green). In every embryonic kidney
we tested, epithelia with adjacent SRIF staining (Fig. 3A,
arrow) also expressed GFP (Fig. 3B) as observed clearly
on merged images (Fig. 3C). Control experiments with
SRIF antiserum followed by antirabbit Cy3 FAB anti-
body fragments (Fig. 3D) and SRIF antiserum followed
by Cy3 FAB fragments and then antirabbit Cy2 antibod-
ies (Fig. 3F) all demonstrated staining at/near basolateral
surfaces on red filters (arrowheads). When we overex-
posed the green filters, both the SRIF/FAB Cy3 (Fig. 3E)
and the SRIF/FAB Cy3/Cy2 (Fig. 3G) images revealed
minor spectral overlap (arrowheads) and some persistent
direct fluorescence from the GFP, but no apparent cross-
reactivity of the Cy2 secondary with SRIF antibody/FAB
Cy3 complexes. To then determine whether the ureteric
bud was likely secreting SRIF at its basolateral surface,
we performed staining for somatostatin and Golgi ap-
paratus on several adjacent serial sections of wild type
E14.5 kidneys. While somatostatin was present at/near
the ureteric bud basolateral surface as expected, (Fig. 3H,
concave arrow) ureteric bud staining for the Golgi appa-
ratus appeared at the lumenal surface (Fig. 3I, concave ar-
rowhead), suggesting that SRIF was not being secreted by
the ureteric bud [the other Golgi-positive signal is present
in the surrounding mesenchyme (Fig. 3I)]. Thus, we con-
cluded that in young embryos, somatostatin was present
at the interface of the metanephric mesenchyme and the
basolateral surface of ureteric bud epithelia.
To characterize the timing and pattern of somatostatin
expression along the basolateral ureteric bud, we exam-
ined several Hoxb7GFP embryonic and postnatal kidney
sections dual-labeled for SRIF (red) and either GFP or
pan-cytokeratin (green) to label the ureteric bud epithelia
(Fig. 4). In cross-sections of E12.5 kidneys, we observed
SRIF staining around the main central ureteric bud trunk
(Fig. 4A, arrow) and around the first two branches from
the main trunk (Fig. 4B, arrows). In longitudinal sec-
tions capturing the first two and subsequent branches
of the ureteric bud, we detected SRIF labeling around
the trunks (Fig. 4C, arrows) but not at outer bud tips
(Fig. 4C, arrowheads). By E14.5, SRIF expression per-
sisted along many early ureteric bud trunks (Fig. 2A).
In addition, as new ureteric bud ampullae just began di-
viding (Fig. 4D), we observed somatostatin expression
at/near the midline clefts (arrow) but not at the early
tips (arrowheads). As the ampullae continued to divide,
SRIF staining persisted along the medial edges of the
emerging ureteric bud trunks (Fig. 4E and F, arrows).
By E16.5, SRIF expression continued at ampullary clefts
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Fig. 2. Immunofluorescence for somato-
statin (SRIF) with and without immunizing
antigen in developing and adult mouse
tissues. (A and B) Staining at/near baso-
lateral tubular surfaces in embryonic (E)
E14.5 kidneys (A, arrows) is blocked by
immunizing antigen (B, arrowheads). (C and
D) Cytoplasmic/lumenal tubular staining
in E16.5 medulla (C, arrow) is blocked by
immunizing antigen (D, arrowhead). (E
and F) Adult kidney medullary staining (E,
arrow) is blocked by preincubation with
immunizing peptide (F, arrowhead). (G to
J) Adult kidney medullary staining (G and
I) is not blocked by preincubation with
cortistatin (H) or urotensin II (J). (K and L)
Staining in fourth layer of cerebral cortex
(Cor) and hippocampus (Hc) (K, arrows)
in brain is blocked by immunizing antigen
(L, arrowheads) (A to D and K and L 200×
magnification; E and F 100× magnification;
G to J 40× magnification).
Fig. 3. Characterization of embryonic kid-
ney epithelium with somatostatin (SRIF) im-
munofluorescence at/near its basolateral sur-
face. (A to C) In HoxB7GFP transgenic mice,
dual-labeled embryonic (E) E14.5 embryonic
kidney epithelia with SRIF staining at/near its
basolateral surfaces (A, red, arrow) and green
fluorescent protein (GFP)-positive ureteric
bud tissue (B, green) overlap on merged im-
ages (C). (D to G) Dual-labeling controls.
SRIF antiserum followed by antirabbit cya-
nine (Cy) Cy3 FAB antibody fragments re-
sults in linear staining on red filters (D, ar-
rowhead) and minor spectral overlap (and
persistent direct fluorescence from the GFP)
on overexposed green filters (E). Addition of
Cy2-conjugated antirabbit antibodies (used to
label the GFP antibody) resulted in similar
staining on both the red filters (F) and the
green filters (G). (H and I) In adjacent sec-
tions of wild-type E14.5 mice, SRIF labeling
is along the basolateral surface of the ureteric
bud (H, concave arrow), whereas Golgi appa-
ratus staining is present at the lumenal surface
of the ureteric bud (I, concave arrowhead)
(200× magnification).
and along medial basolateral edges of emerging cortical
ureteric bud trunks (Fig. 4G to I); however, SRIF stain-
ing at/near the basolateral ureteric bud was absent in the
maturing medulla (see Fig. 5). By E18.5, SRIF staining
at/near basolateral epithelial surfaces was present only
along immature ureteric bud tissues at the outer cortex
in the same pattern as younger embryos (Fig. 4J). By P14,
when all ureteric bud branching had ceased, we did not
detect any somatostatin immunostaining at basolateral
epithelia in the cortex (Fig. 5G). Thus, we concluded that
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Fig. 4. Merged immunofluorescent images of
somatostatin (SRIF) (red) and markers of the
ureteric bud (green) in embryonic kidneys
of different ages. (A and B) Cross-sections
of embryonic (E) E12.5 kidneys show SRIF
staining around the main central ureteric bud
trunk (A, arrow) and the first two branches (B,
arrows). (C) Longitudinal sections of E12.5
kidneys reveal SRIF labeling around trunks
(arrows) but not outer tips (arrowheads) of
the first two and subsequent ureteric bud
branches. (D) E14.5 kidneys show SRIF ex-
pression at/near midline clefts of dividing
ureteric bud ampullae (arrow) and not at
the early tips (arrowheads). (E and F) E14.5
kidneys demonstrate persistent SRIF stain-
ing along medial edges of emerging ureteric
bud trunks as ampullae continue to divide (ar-
rows). (G to I) E16.5 kidneys show SRIF ex-
pression at new ampullary clefts (G, arrow)
and along medial edges of emerging cortical
ureteric bud trunks (H and I, arrows), but not
at outer tips (G, arrowhead). (J) E18.5 kid-
neys demonstrate SRIF staining around baso-
lateral surfaces of ureteric bud epithelia (ar-
rows) at the outer cortex with the same pat-
tern as younger embryos (A to C 100× magni-
fication; G to J 200× magnification). Abbre-
viations are: GFP, anti-green fluorescent pro-
tein; pan, anti-pan cytokeratin.
Fig. 5. Fluorescent micrograph showing lo-
calization of medullary lumenal somatostatin
(SRIF) staining at E16.5 and persistence of
medullary staining at postnatal (P) P14. (A
to C) Embryonic (E) E16.5 kidney tubules
with lumenal SRIF staining (A, red, arrow)
and green fluorescent protein (GFP)-positive
ureteric bud epithelia (B, green, arrowhead)
do not overlap on merged images (C). (D to
F) E16.5 kidney tubules with lumenal SRIF
expression (D, arrow) always colabel with
aquaporin-1 (AQP-1) (E, arrow) on merged
images (F), although some AQP-1–positive
tubules do not express SRIF (concave arrow-
heads). (G and H) At P14, SRIF labeling is
now completely absent in the renal cortex
(G), but persists in many medullary tubules
(H, arrow). (I to L) Dual-labeling controls.
SRIF antiserum followed by antirabbit cya-
nine (Cy) Cy3 FAB antibody fragments re-
sults in lumenal staining on red filters (I, con-
cave arrow) and minor spectral overlap (and
persistent direct fluorescence from the GFP)
on overexposed green filters (J); addition of
Cy2-conjugated antirabbit antibodies (used to
label the GFP antibody) showed similar stain-
ing on both the red filters (K) and the green
filters (L) (A to F and I to L 200× magnifica-
tion; G and H 100× magnification).
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Fig. 6. Dual-labeling immunofluorescence
of somatostatin (SRIF) (green) and localizing
markers (red) in the adult kidney medulla.
(A to C) SRIF (A, arrow) and aquaporin-1
(AQP-1) (B, green), a marker of the thin
descending limb of Henle, completely
overlap on merged images (C, arrow). (D
to F) SRIF (D, arrow) and the collecting
duct marker AQP-2 (E, arrowhead) are
not coexpressed on merged images (F). (G
to I) SRIF (G, arrow) and Tamm-Horsfall
protein (THP) (H, concave arrowhead), a
marker of the thick ascending limb of Henle,
do not overlap on merged images (I). (J to
M) Controls. AQP-1 antiserum followed by
antirabbit FAB fragments with cyanine (Cy)
Cy3 results in bright tubular cell staining
(concave arrows) on red filters (J) and no
spectral overlap on overexposed green filters
(K); addition of Cy2-conjugated antirabbit
antibodies (used to label the SRIF antibody)
resulted in similar staining on red filters
(L) and demonstrated no spectral overlap
or cross reactivity with AQP-1/FAB Cy3
antibody complexes on overexposed green
filters (M) (200× magnification).
somatostatin protein is first expressed at/near the baso-
lateral surfaces of early main ureteric bud trunks and then
at ampullary clefts and subsequent ureteric bud trunks,
but never near ureteric bud tips.
In E16.5 kidneys, while SRIF staining at/near the baso-
lateral ureteric bud surface was present only in the cortex,
we observed lumenal somatostatin staining in medullary
tubules (Fig. 5). To determine if these were also ureteric
bud tissues, we performed dual labeling in Hoxb7 trans-
genic mice for somatostatin (Fig. 5A, arrow) and GFP
(Fig. 5B, arrowhead), but observed no overlapping ex-
pression on merged images (Fig. 5C). To determine if the
medullary tubules were maturing thin descending limbs
of Henle, we then performed dual labeling for SRIF and
AQP-1. We observed that every somatostatin positive
tubule (Fig. 5D, arrow) also expressed AQP-1 (Fig. 5E,
arrow) on merged images (Fig. 5F); however, a few AQP-
1 positive tubules did not express somatostatin (con-
cave arrowheads). By E18.5, lumenal SRIF staining was
present on a large number of medullary tubules that all
expressed AQP-1, although as in E16.5 kidneys, a small
number of AQP-1–positive tubules did not express so-
matostatin (not shown). In P14 kidneys (when nephroge-
nesis was finished), somatostatin was present exclusively
in medullary tubules (Fig. 5G and H). Control experi-
ments with SRIF antiserum followed by antirabbit Cy3
FAB antibody fragments (Fig. 5I) and SRIF antiserum
followed by Cy3 FAB fragments and then antirabbit Cy2
antibodies (Fig. 5K) all demonstrated luminal staining
on red filters (concave arrows). When we overexposed
the green filters, both the SRIF/FAB Cy3 (Fig. 5J) and
the SRIF/FAB Cy3/Cy2 (Fig. 5L) images revealed minor
spectral overlap (concave arrows) and some persistent
direct fluorescence from the GFP (arrowheads), but no
apparent cross-reactivity of the Cy2 secondary with SRIF
antibody/FAB Cy3 complexes. Thus, we concluded that
in older embryos and young postnatal mice, somatostatin
is present in maturing medullary thin descending limbs of
Henle.
To identify the medullary tubules expressing so-
matostatin protein in the adult kidney, we performed
dual-labeling immunofluorescence with SRIF antiserum
(green) and localizing markers (red) (Fig. 6). So-
matostatin (Fig. 6A, arrow) and AQP-1 (Fig. 6B, ar-
row), a marker of thin descending limbs of the Henle
loop, demonstrated complete overlapping expression
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on merged images (Fig. 6C, arrow). In contrast, SRIF
(Fig. 6D, arrow) did not colabel with AQP-2 (Fig. 6E,
arrowhead) in the collecting duct on merged images
(Fig. 6F). Somatostatin (Fig. 6G, arrow) was also not
coexpressed with THP (Fig. 6H, concave arrowhead),
a marker of the thick ascending limb of Henle, on
merged images (Fig. 6I). Furthermore, unlike thick as-
cending limbs that are only present in the outer medulla,
somatostatin-expressing tubules were located in both the
inner and outer medulla (Fig. 6I). Control experiments
demonstrated no spectral overlap of red anti-AQP-1/anti-
rabbit FAB Cy3 antibody complexes (Fig. 6J) on overex-
posed green filters (Fig. 6K); addition of Cy2-conjugated
antirabbit antibodies (used to label the SRIF antibody)
resulted in similar staining on red filters (Fig. 6L) and
demonstrated no spectral overlap or cross reactivity with
AQP-1/FAB Cy3 antibody complexes on overexposed
green filters (Fig. 6M). Thus, we concluded that the adult
mouse kidney tubules expressing somatostatin protein
were the medullary thin descending limbs of Henle.
DISCUSSION
In this study, we describe the presence of somatostatin
mRNA and protein in both the adult and developing
mouse kidney. The expression pattern of SRIF in the
adult mouse kidney is surprisingly different than what was
reported in the rat. Whereas we detected strong expres-
sion in mouse medullary thin descending limbs of Henle,
no tubular expression was described in the rat [9]. One ex-
planation could be that we fixed our mouse kidneys with
Histochoice, while the other group used paraformalde-
hyde (PFA) to fix the rat kidneys [9]. Histochoice is an
alcohol based fixative that has been shown to cause less
cross-linking than PFA, often resulting in superior im-
munostaining signal strength [20]. As has happened with
other antisera we have used for other studies, both SRIF
antisera we utilized in this study did not give any specific
immunostaining signal in PFA-fixed mouse kidneys (not
shown). Why we did not detect the presence of somato-
statin in mouse glomeruli, as was reported in the rat, is
not as clear. The reported SRIF immunostaining in rat
kidneys was very sparse (only one out of every five to ten
glomeruli) and in unidentified cells that were not thought
to be any of the usual cells known to populate glomeruli
(i.e., epithelial cells, endothelial cells, or mesangial cells)
[9]. Despite using two different antibodies against SRIF,
we did not find expression in such cells in the mouse (al-
though the tubular staining was the same with both anti-
bodies).
While the reported staining pattern for somatostatin
in rat kidneys contrasted greatly with the expression pro-
file in human kidney cells, there were some similarities
between what we found in mice and what was found
in humans. Heterogeneous mixtures of cultured human
tubular cells expressed somatostatin mRNA by both RT-
PCR and Northern blotting and were capable of secreting
the peptide into the media [10]. The particular cells that
constituted the cultures were not identified with molec-
ular markers, and thus may have included thin descend-
ing limbs of Henle that were expressing the peptide. In a
separate report, human mesangial cell cultures expressed
somatostatin mRNA by RT-PCR and secreted the pep-
tide into media [8], while as noted above, we found no
SRIF staining in mouse glomeruli. Although somato-
statin expression patterns in humans and rodents are usu-
ally comparable, there are exceptions. For instance, SRIF
mRNA is expressed in the granular cell layer of rat cere-
bellum, whereas it is not found in the human cerebellum
[21]. Thus, the absence of somatostatin staining in mouse
glomeruli (while it is present in human mesangial cells)
may represent a species-related difference in SRIF ex-
pression patterns.
In addition to SRIF, we have we have previously found
that somatostatin receptors are expressed in the adult
mouse kidney (in glomeruli, proximal tubules, and col-
lecting ducts) [12, 22]. This implied paracrine/autocrine
signaling in the adult kidney has been described in many
other organs such as the brain [21], the pancreas [1, 23],
the retina [24], ovarian tumors [25], and neuroblastomas
[26]. In the adult kidney, SRIF may be secreted by cells
of the thin descending limb of Henle into the tubular lu-
men to bind its collecting duct receptors downstream; the
peptide may also be secreted into the peritubular vascu-
lature to be circulated back to its receptors in glomeruli
and proximal tubules. Although no published data ex-
ist on somatostatin receptor expression in the embryonic
kidney, in immature regions of the developing kidney,
the local vasculature has not yet formed; thus, the pep-
tide is likely produced locally. Furthermore, based of the
localization data with Golgi markers, the cells producing
somatostatin are unlikely to be ureteric bud cells.
While somatostatin has many actions in the adult kid-
ney (see above), its presence in the developing kidney is
a completely novel finding and its actions there are un-
known. In other rapidly growing tissues, somatostatin has
very potent antiproliferative effects. Somatostatin or its
analogues blunt growth rates of human pituitary tumors,
endocrine pancreatic tumors, mammary tumors, and car-
cinoids that express SSTRs [25, 27, 28]. Most of the T
and B lymphocytes with somatostatin receptors prolifer-
ate less when treated with ligand [29]. Somatostatin or
its analogues also dramatically reduce rates of prolifer-
ation in gut mucosal epithelium as measured in rabbit
ileal organ cultures [30] and in rat intestines in vivo [31,
32]. Fetal cartilage and bone precursor cells also express
SSTRs and display blunted growth rates after treatment
with somatostatin [1]. In the developing kidney, the mid-
line clefts of the ureteric bud ampullae and the emerging
ureteric bud trunks do not proliferate as rapidly as the
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expanding ureteric bud tips [11]. Perhaps SRIF acts on the
former tissues or mesenchymal tissues to decrease prolif-
eration rates as is necessary for the proper formation of
the kidney. The identification of somatostatin receptors
in the developing kidney would provide more evidence
that SRIF is acting locally.
CONCLUSION
We have detected the expression of somatostatin
mRNA in both developing and adult mouse kidneys. In
developing kidneys, somatostatin first appears at the in-
terface of the metanephric mesenchyme and the basolat-
eral surfaces of the ureteric bud central trunks; later SRIF
appears at/near the midline clefts of ureteric bud ampul-
lae and on the medial surfaces of the emerging ureteric
bud trunks. In older embryonic kidneys, somatostatin is
expressed in maturing medullary tubules that label with
markers of the thin descending limb of Henle. In adult
kidneys, somatostatin proteins are exclusively expressed
in medullary thin descending limbs of the Henle loop.
Finally, the presence of somatostatin and its receptors
in the adult mouse kidney implies paracrine/autocrine
signaling.
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